Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.51
SNY's Cash to Debt is ranked higher than
60% of the 921 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. SNY: 0.51 )
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.51

Equity to Asset 0.58
SNY's Equity to Asset is ranked higher than
68% of the 842 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. SNY: 0.58 )
SNY' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.65
Current: 0.58

0.48
0.65
Interest Coverage No Debt
SNY's Interest Coverage is ranked higher than
80% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 176.76 vs. SNY: No Debt )
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 9999.99
Current: No Debt

7.88
9999.99
F-Score: 8
Z-Score: 2.49
M-Score: -2.74
WACC vs ROIC
7.77%
12.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.01
SNY's Operating margin (%) is ranked higher than
88% of the 870 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.37 vs. SNY: 18.01 )
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 18.01

15.25
38.21
Net-margin (%) 12.87
SNY's Net-margin (%) is ranked higher than
86% of the 870 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. SNY: 12.87 )
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.87

7.92
25.8
ROE (%) 13.33
SNY's ROE (%) is ranked higher than
86% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. SNY: 13.33 )
SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 13.33

5.18
33.55
ROA (%) 7.72
SNY's ROA (%) is ranked higher than
86% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. SNY: 7.72 )
SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 7.72

2.62
21.59
ROC (Joel Greenblatt) (%) 64.81
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. SNY: 64.81 )
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.22   Max: 145.55
Current: 64.81

31.22
145.55
Revenue Growth (3Y)(%) -100.00
SNY's Revenue Growth (3Y)(%) is ranked lower than
53% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. SNY: -100.00 )
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 27.4
Current: -100

-100
27.4
EBITDA Growth (3Y)(%) -100.00
SNY's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. SNY: -100.00 )
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -100   Max: 35.7
Current: -100

-100
35.7
EPS Growth (3Y)(%) -100.00
SNY's EPS Growth (3Y)(%) is ranked lower than
51% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNY: -100.00 )
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -100   Max: 41.2
Current: -100

-100
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SNY Guru Trades in Q1 2014

Bill Nygren 2,600,000 sh (New)
Scott Black 247,100 sh (New)
John Buckingham 20,080 sh (New)
Steven Cohen 300,000 sh (New)
Manning & Napier Advisors, Inc 2,923,087 sh (+836.86%)
HOTCHKIS & WILEY 9,804,594 sh (+65.83%)
James Barrow 27,790,116 sh (+22.72%)
Sarah Ketterer 506,901 sh (+17.52%)
PRIMECAP Management 2,476,856 sh (+8.58%)
Charles Brandes 2,072,790 sh (+2.95%)
Ken Fisher 12,926,402 sh (+0.84%)
Dodge & Cox 43,664,887 sh (+0.08%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
John Hussman 22,100 sh (unchged)
Third Avenue Management 15,706 sh (-2.48%)
NWQ Managers 5,460,055 sh (-6.39%)
Jean-Marie Eveillard 610,749 sh (-6.68%)
» More
Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.30%)
Ken Fisher 13,079,575 sh (+1.18%)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
Jean-Marie Eveillard 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
Jean-Marie Eveillard 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

David Dreman 1,102 sh (New)
Steven Cohen 1,050,000 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
Francis Chou 410,000 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Jean-Marie Eveillard 34,157 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
sing the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were held by the highest number of gurus. Read more...
Oakmark Funds' Bill Nygren Buys 4 New Stocks
Bill Nygren (Trades, Portfolio)’s Oakmark fund beat the S&P 500 for the first quarter with a 5% gain compared to the index’s 2% rise. In his first quarter letter, he attributed the strong quarter primarily to Forest Laboratories being acquired by Actavis Plc (ACT), and large exposure to auto-related cyclical and financials. Read more...
Bill Nygren Comments on Sanofi
Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.00
SNY's P/E(ttm) is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.40 vs. SNY: 27.00 )
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 38.97
Current: 27

9.64
38.97
Forward P/E 8.54
SNY's Forward P/E is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.57 vs. SNY: 8.54 )
N/A
PE(NRI) 28.10
SNY's PE(NRI) is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.00 vs. SNY: 28.10 )
SNY' s 10-Year PE(NRI) Range
Min: 9.82   Max: 39.2
Current: 28.1

9.82
39.2
P/B 2.20
SNY's P/B is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. SNY: 2.20 )
SNY' s 10-Year P/B Range
Min: 1.11   Max: 5.88
Current: 2.2

1.11
5.88
P/S 3.60
SNY's P/S is ranked higher than
65% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.26 vs. SNY: 3.60 )
SNY' s 10-Year P/S Range
Min: 1.77   Max: 5.18
Current: 3.6

1.77
5.18
PFCF 14.90
SNY's PFCF is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 639.25 vs. SNY: 14.90 )
SNY' s 10-Year PFCF Range
Min: 5.11   Max: 45
Current: 14.9

5.11
45
POCF 12.13
SNY's POCF is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 37.05 vs. SNY: 12.13 )
SNY' s 10-Year POCF Range
Min: 4.15   Max: 23.37
Current: 12.13

4.15
23.37
EV-to-EBIT 21.31
SNY's EV-to-EBIT is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.20 vs. SNY: 21.31 )
SNY' s 10-Year EV-to-EBIT Range
Min: 10.5   Max: 204.2
Current: 21.31

10.5
204.2
Shiller P/E 23.60
SNY's Shiller P/E is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.29 vs. SNY: 23.60 )
SNY' s 10-Year Shiller P/E Range
Min: 11.35   Max: 25.07
Current: 23.6

11.35
25.07
Current Ratio 1.80
SNY's Current Ratio is ranked higher than
64% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. SNY: 1.80 )
SNY' s 10-Year Current Ratio Range
Min: 0.79   Max: 2.71
Current: 1.8

0.79
2.71
Quick Ratio 1.29
SNY's Quick Ratio is ranked higher than
63% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. SNY: 1.29 )
SNY' s 10-Year Quick Ratio Range
Min: 0.46   Max: 2.41
Current: 1.29

0.46
2.41
Days Inventory 191.96
SNY's Days Inventory is ranked higher than
64% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. SNY: 191.96 )
SNY' s 10-Year Days Inventory Range
Min: 155.87   Max: 224.59
Current: 191.96

155.87
224.59
Days Sales Outstanding 76.50
SNY's Days Sales Outstanding is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. SNY: 76.50 )
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29   Max: 103.32
Current: 76.5

61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.80
SNY's Dividend Yield is ranked higher than
94% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. SNY: 3.80 )
SNY' s 10-Year Dividend Yield Range
Min: 1.41   Max: 5.46
Current: 3.8

1.41
5.46
Dividend Payout 0.84
SNY's Dividend Payout is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 0.84 )
SNY' s 10-Year Dividend Payout Range
Min: 1.17   Max: 8.15
Current: 0.84

1.17
8.15
Dividend growth (3y) -100.00
SNY's Dividend growth (3y) is ranked higher than
60% of the 364 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. SNY: -100.00 )
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.1
Current: -100

0
22.1
Yield on cost (5-Year) 3.80
SNY's Yield on cost (5-Year) is ranked higher than
86% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. SNY: 3.80 )
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.41   Max: 5.46
Current: 3.8

1.41
5.46
Share Buyback Rate 100.00
SNY's Share Buyback Rate is ranked higher than
100% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. SNY: 100.00 )
SNY' s 10-Year Share Buyback Rate Range
Min: 100   Max: -24.6
Current: 100

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 50.30
SNY's Price/Tangible Book is ranked lower than
60% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.88 vs. SNY: 50.30 )
SNY' s 10-Year Price/Tangible Book Range
Min: 6.59   Max: 2093.5
Current: 50.3

6.59
2093.5
Price/DCF (Projected) 0.90
SNY's Price/DCF (Projected) is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.40 vs. SNY: 0.90 )
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.52   Max: 5.65
Current: 0.9

0.52
5.65
Price/Median PS Value 1.20
SNY's Price/Median PS Value is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. SNY: 1.20 )
SNY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 8.62
Current: 1.2

0.64
8.62
Price/Graham Number 7.70
SNY's Price/Graham Number is ranked higher than
65% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. SNY: 7.70 )
SNY' s 10-Year Price/Graham Number Range
Min: 1.94   Max: 45.51
Current: 7.7

1.94
45.51
Earnings Yield (Greenblatt) 4.80
SNY's Earnings Yield (Greenblatt) is ranked higher than
84% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 4.80 )
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.5
Current: 4.8

0.5
9.5
Forward Rate of Return (Yacktman) 2.26
SNY's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 520 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. SNY: 2.26 )
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10   Max: 48.2
Current: 2.26

-10
48.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SANNV.France, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Scottrade Mar 23 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 
Dodge & Cox's Stock Fund Q4 2014 Commentary Jan 20 2015 
Guru Stocks at 52-Week Lows: GOOG, VZ, HSBC, SNY, TOT Jan 12 2015 


More From Other Websites
Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog Mar 26 2015
Genzyme Convenes Sixth Annual Gaucher Leadership Forum Mar 26 2015
ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy... Mar 25 2015
Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years... Mar 25 2015
Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog Mar 24 2015
11 Promising New Drugs Expected to Make Billions in Sales Mar 23 2015
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog Mar 20 2015
Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog Mar 20 2015
Goldman Downgrade Makes MannKind A Buy Mar 20 2015
Evotec and Sanofi Sign Definitive Agreement for Major Multi-Component Strategic Alliance Mar 19 2015
Mark Levin to be honored with MassBio's annual Termeer award Mar 19 2015
Amicus Up As FDA, EU Green-light Quick Drug Filings Mar 19 2015
Novo Nordisk On Diversity In Diabetes Trials: "We Could Do Better" Mar 19 2015
5 Breakout Stocks to Trade for Gains After the Fed's Bombshell Mar 19 2015
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) Mar 19 2015
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide) Mar 19 2015
Investors Relieved? Akorn Stock Retakes 50-Day Line Mar 18 2015
To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher Mar 18 2015
The Temptation of International Dividend ETFs Mar 18 2015
Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog Mar 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK